Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature.
To date, there is no standard treatment for patients with metastatic non-small-cell lung cancer after multiple previous lines of chemotherapy. Pemetrexed in combination with cisplatin or as a single agent demonstrated significant activity in patients with nonsquamous non-small-cell lung cancer with a good toxicity profile. In this article, we present a case of pulmonary adenocarcinoma treated with pemetrexed after five lines of treatment, including the cytotoxic agents cisplatin plus vinorelbine, docetaxel, gemcitabine and the tyrosine kinase inhibitor erlotinib. We also review the role of pemetrexed in this setting of patients.